Abstract
The antifungal drug ketoconazole, a cytochrome P450 inhibitor, has been shown to inhibit renal 1,25-dihydroxyvitamin D production in vitro and to lower serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with primary hyperparathyroidism. To assess the usefulness of this drug in the hypercalcemia of sarcoidosis, a condition thought to result from over-production of 1,25-dihydroxyvitamin D by sarcoid-involved tissues, two men with sarcoidosis, hypercalcemia, and elevated serum levels of 1,25-dihydroxy-vitamin D were given ketoconazole, 600–800 mg per day, for four to six days. Serum 1,25-dihydroxyvitamin D levels were markedly reduced (by approximately 40%) in both patients during ketoconazole administration, but serum calcium was not affected. In both patients, renal function deteriorated during ketoconazole treatment. We conclude that ketoconazole administration can lower the elevated serum 1,25-dihydroxyvitamin D levels in sarcoidosis. However, deterioration of renal function during ketoconazole administration as well as failure of hypercalcemia to be affected during short-term ketoconazole treatment suggest that this drug might not be appropriate for acute treatment of hypercalcemic sarcoidosis.
Similar content being viewed by others
References
Meyrier A., Valeyre D., Bouillon R., Paillard F., Battesti J.-P., Georges R. Resorptive versus absorptive hypercalciuria in sarcoidosis: correlations with 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 and parameters of disease activity. Quart. J. Med. 54: 269, 1985.
Sharma O.P. Hypercalcemia in sarcoidosis: the puzzle finally solved. Arch. Intern. Med. 145: 626, 1985.
Singer F.R., Adams J.S. Abnormal calcium homeostasis in sarcoidosis. N. Engl. J. Med. 315: 755, 1986.
Papapoulos S.E., Fraher L.H., Sandler L.M., Clemens T.L., Lewin I.G., O’Riordan J.L.H. 1,25-dihydroxycholecalciferol in the pathogenesis of the hypercalcemia of sarcoidosis. Lancet 1: 627, 1979.
Bell N.H., Stern H., Pantzer E., Sinha T.K., De Luca H.F. Evidence that increased circulating 1,25-dihydroxy-vitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J. Clin. Invest. 64: 218, 1979.
Koide Y., Kugai N., Kimura S., Fujita T., Yamashita N., Hiramoto T., Sukegawa J., Ogata E., Yamashita K. Increased 1,25-dihydroxycholecalciferol as a cause of abnormal calcium metabolism in sarcoidosis. J. Clin. Endocrinol. Metab. 52: 494, 1981.
Sandler L.M., Winearls C.G., Fraher L.J., Clemens T.L., Smith R., O’Riordan J.L.H. Studies of the hypercalcemia of sarcoidosis: effect of steroids and exogenous vitamin D3 on the circulating concentrations of 1,25-dihydroxyvitamin D3. Quart. J. Med. 53: 165, 1984.
Insogna K.L., Dreyer B.E., Mitnick M., Ellison A.F., Broadus A.E. Enhanced production rate of 1,25-dihydroxyvitamin D in sarcoidosis. J. Clin. Endocrinol. Metab. 66: 72. 1988.
Barbour G.L., Coburn J.W., Slatapolsky E., Norman A.W., Horst R.L. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N. Engl. J. Med. 305: 440, 1981.
Maesaka J.K., Batuman V., Pablo N.C., Shakamuri S. Elevated 1,25-dihydroxyvitamin D levels: occurrence with sarcoidosis with end-stage renal disease. Arch. Intern. Med. 142: 1206, 1982.
Adams J.S., Sharma O.P., Gacad M.A, Singer F.R. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J. Clin. Invest. 72: 1856, 1983.
Mason R.S., Frankel T., Chan Y.L., Lissner D., Posen S. Vitamin D conversion by sarcoid lymph node homogenate. Ann. Intern. Med. 100: 59, 1984.
Adams J.S., Singer F.R., Gacad M.A., Sharma O.P., Hayes M.J., Vouros P., Holick M.F. Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. J. Clin. Endrocrinol. Metab. 60: 960, 1985.
Reichel H., Koeffler H.P., Barbers R., Norman A.W. Regulation of 1,25-dihydroxyvitamin D3 production by cultured alveolar macrophages from normal human donors and from patients with pulmonary sarcoidosis. J. Clin. Endocrinol. Metab. 65: 1201, 1987.
Henry H.L. Effect of ketoconazole and miconazole on 25-hydroxyvitamin D3 metabolism by cultured chick kidney cells. J. Steroid Biochem. 23: 991, 1985.
Glass A.R., Eil C. Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D. J. Clin. Endocrinol. Metab. 63: 766, 1986.
Glass A.R., Eil C. Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D and total serum calcium in hypercalcemic patients. J. Clin. Endocrinol. Metab. 66: 934, 1988.
Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr. Rev. 7: 409, 1986.
Stevens D.A. Ketoconazole metamorphosis. An antimicrobial becomes an endocrine drug. Arch. Intern. Med. 145: 813, 1985.
Sonino N. The endocrine effects of ketoconazole. J. Endocrinol. Invest. 9: 341, 1986.
Mason R.S., Pryke A.M., White C.P. The effect of ketoconazole on seco-steroid synthesis in alveolar macrophages. Proceedings Endocrine Society Australia 1987 (Abstract).
Adams J.S., Sharma O.P., Diz M.M., Endres D.B. Ketaconazole and chloroquine in the management of 1,25-dihydroxyvitamin D-mediated hypercalcemia associated with sarcoidosis:: potential clinical utility and mechanism of action. J. Bone Miner. Res. 4 (Suppl. 1): S314, 1989 (Abstract).
Adams J.S., Sharma O.P., Diz M.M., Endres D.B. Ketoconazole decreases the serum 1,25 dihydroxy-vitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J. Clin. Endocrinol. Metab. (in press).
Author information
Authors and Affiliations
Additional information
The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.
Fundmg was provided by the Department of Clinical Investigation, Walter Reed Army Medical Center and by USPHS grants RR-00058, DK-15089 and DK-22014.
Rights and permissions
About this article
Cite this article
Glass, A.R., Cerletty, J.M., Elliott, W. et al. Ketoconazole reduces elevated serum levels of 1,25-dihydroxy vitamin D in hypercalcemic sarcoidosis. J Endocrinol Invest 13, 407–413 (1990). https://doi.org/10.1007/BF03350691
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350691